Fate Therapeutics Inc
(STU:F6T)
€
2.206
+0.034 (+1.57%)
Market Cap: 266.47 Mil
Enterprise Value: 198.76 Mil
PE Ratio: 0
PB Ratio: 1.95
GF Score: 39/100 Fate Therapeutics, Inc. Presents at Citi's 14th Annual Biotech Conference, Sep-04-2019 01:30 PM Transcript
Sep 04, 2019 / 05:30PM GMT
Release Date Price:
€14.71
(-2.70%)
Yigal Dov Nochomovitz
Citigroup Inc, Research Division - Director
The next panel is cell therapy, up-and-comers in the cell therapy space. So it's my pleasure to introduce our 3 distinguished guests, from Atara the CEO, Pascal Touchon; and from Cellectis, André Choulika; and, of course, from Fate, in the middle, Scott Wolchko. So welcome all of you. Thanks for making the time.
Questions & Answers
Yigal Dov Nochomovitz
Citigroup Inc, Research Division - Director
I guess the question I have to start out the session is at a 30,000-foot level, could each of you give your thoughts on what are the ingredients to create a successful cell therapy? What are the things you want to do? And what are the things that you absolutely want to avoid on the path to a product that's a cell-based therapy? So you want to kick it off, Pascal?
Pascal Touchon;Yigal Dov Nochomovitz<
Atara Biotherapeutics, Inc. - President, CEO & Director
Yes, with pleasure. I mean thank you for inviting me, by the way.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot